Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ursodiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 known ✓ | Q96RI1 | 7/20 | 0.98 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.98 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.98 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ursodiol SCHEMBL8829737 | 1.00 | GPBAR1 (0.98) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL61536 | 1.00 | GPBAR1 (0.98) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL23704676 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL22108119 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL22384718 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24199134 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25337643 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24061005 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL23517166 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25337648 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102631313-A | Polyene phosphatidyl choline intravenous administration preparation and preparation method thereof | SHANGHAI TIANSHILI MEDICAL TECHNOLOGY CO LTD | 2012-08-15 | — | — | CN | claimed |
| CN-1329502-A | Pharmaceutical compositions containing insulin | PROVALIS UK LTD (GB) | 2002-01-02 | — | — | CN | claimed |
| CN-118217294-A | Ursodeoxycholic acid compound and preparation method thereof | 成都赛璟生物医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118019522-A | Pharmaceutical composition comprising a large physiologically active substance and an excipient | D&D制药技术股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-11976063-B2 | Pharmaceutical composition comprising berberine and ursodeoxycholic acid for the treatment of various diseases or disorders | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2024-05-07 | — | — | US | disclosed |
| US-20230348457-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL LTD (CN) | 2023-11-02 | — | — | US | disclosed |
| CN-116940384-A | Oral formulations having bioactive material conjugates coupled to biotin moieties, fatty acid moieties, or combinations thereof | D&D制药技术股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230295151-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11685735-B2 | Pharmaceutical composition comprising berberine salts for the treatment of various diseases or disorders | SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| CN-110548037-B | Refined bear gall powder and its use for strengthening physique, treating and preventing tumor and cancer | 江西天元药业有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-110559303-B | Refined bear gall powder for reducing blood fat and preventing and treating cardiovascular and cerebrovascular diseases and atherosclerosis | 江西天元药业有限公司 | 2023-06-02 | — | — | CN | disclosed |
| WO-2004071453-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF POUCHITIS | ISIS PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040162259-A1 | Compositions and methods for treatment of pouchitis | ISIS PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| US-6747014-B2 | FOR THERAPY OF INFLAMMATORY BOWEL DISORDER | ISIS PHARMACEUTICALS, INC. | 2004-06-08 | — | — | US | disclosed |
| EP-1080103-A4 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030040497-A1 | Compositions and methods for non-parenteral delivery of oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| CN-1329502-A | Pharmaceutical compositions containing insulin | PROVALIS UK LTD (GB) | 2002-01-02 | — | — | CN | disclosed |
| EP-1080103-A1 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999060012-A1 | COMPOSITIONS AND METHODS FOR NON-PARENTERAL DELIVERY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| EP-0576938-A1 | Composition of digestive enzymes and salts of bile acids and process for preparation thereof | DIGESTIVE CARE INC. (US) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348457-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | CYP27A1, NR1H4, CYP7A1 | NR1H4 2/4885GPBAR1 12/4885ABCB11 67/4885 |
| US-11685735-B2 | Pharmaceutical composition comprising berberine salts for the treatment of various diseases or disorders | CPT1B, CYP27A1, GLS2 | NR1H4 7/4885GPBAR1 13/4885ABCB11 74/4885 |
| US-20230295151-A1 | BERBERINE SALTS, URSODEOXYCHOLIC SALTS AND COMBINATIONS, METHODS OF PREPARATION AND APPLICATION THEREOF | CYP27A1, NR1H4, CYP7A1 | NR1H4 2/4885GPBAR1 12/4885ABCB11 67/4885 |
| US-11976063-B2 | Pharmaceutical composition comprising berberine and ursodeoxycholic acid for the treatment of various diseases or disorders | CYP27A1, NR1H4, CPT1B | NR1H4 2/4885GPBAR1 9/4885ABCB11 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.